Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Am J Med ; 135(8): 1001-1007, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35580718

RESUMEN

BACKGROUND: Angiotensin receptor blockers (ARBs), which are commonly used antihypertensives, have been proposed to lower the risk of Parkinson disease by reducing oxidative stress based on animal and in vitro studies. Thus, this study aimed to test this association in patients with newly diagnosed hypertension. METHODS: This retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension between 2001 and 2013. The hazard ratios for Parkinson disease were calculated for ARB treatment compared with those who never used ARBs and among the 5 subgroups receiving different cumulative ARB dosages. RESULTS: We identified 527 (1.1%) Parkinson disease cases among patients with ARB treatment in a median observation period of 8.4 years compared to the 1,255 (2.2%) Parkinson disease cases among those without ARB treatment in a median observation period of 6.8 years. Overall, risk for developing Parkinson disease was statistically lower in the ARB-treated group with a hazard ratio of 0.56 (95% confidence interval: 0.51-0.63) than those without ARB. CONCLUSIONS: ARB treatment was associated with a statistically important reduction of Parkinson disease risk in patients with newly diagnosed hypertension. Therefore, ARB may constitute an effective neuroprotective strategy to lower Parkinson disease risk in such patients.


Asunto(s)
Hipertensión , Enfermedad de Parkinson , Antagonistas de Receptores de Angiotensina/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Hipertensión/epidemiología , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/epidemiología , Estudios Retrospectivos
2.
NPJ Prim Care Respir Med ; 32(1): 4, 2022 01 17.
Artículo en Inglés | MEDLINE | ID: mdl-35039513

RESUMEN

Patients with chronic obstructive pulmonary disease (COPD) are at higher risk of stroke. This study aimed to investigate the clinical factors of stroke risk in COPD and allied conditions patients and associations between medications for treating COPD and allied conditions. The population-based study cohort comprised 24,173 patients diagnosed with COPD and allied conditions between 2000 and 2013, and 24,170 selected matched patients without COPD comprised the comparison cohort from a nationwide database. Cox-proportional hazard regression was performed to determine the impact of medical therapies, comorbidities, and other clinical factors on stroke risk. Of the 48,343 included patients, 1394 (2.9%) experienced stroke during follow-up, with a significant difference between COPD and allied conditions cohort (1003/4.2%) and comparison cohort (391/1.6%) (adjusted hazard ratio [aHR]: 2.72, p < 0.001). Cox-regression analysis revealed that COPD and allied conditions patients who were older (>65 years) (HR: 1.06); male (HR: 1.39); with hypertension (HR: 1.46), diabetes mellitus (HR: 1.33) and atrial fibrillation (HR: 1.63) had increased stroke risk. Mucolytics (HR: 0.44) and combination therapy with inhaled corticosteroids (ICS) and long-acting ß2-agonists (LABA) (HR: 0.75) were associated with decreased stroke risk in COPD and allied conditions patients. Among COPD and allied conditions patients, major comorbidities increase risk of stroke. Therapy with mucolytic agents and combination ICS/LABA is associated with risk reduction.


Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2 , Enfermedad Pulmonar Obstructiva Crónica , Administración por Inhalación , Corticoesteroides , Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Broncodilatadores/uso terapéutico , Estudios de Cohortes , Quimioterapia Combinada , Humanos , Masculino , Antagonistas Muscarínicos , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/epidemiología
3.
BMC Urol ; 20(1): 108, 2020 Jul 20.
Artículo en Inglés | MEDLINE | ID: mdl-32690002

RESUMEN

BACKGROUND: Hypokalemia is a common clinical problem. The association between urinary tract infection (UTI) and hypokalemia is not clear. Hypokalemia is common in patients with UTI in clinical observation. The aim of the study is to determine if UTI is associated with hypokalemia. METHODS: Patients hospitalized with UTI and the control group were retrieved from the Longitudinal Health Insurance Database 2005. The control group was patients hospitalized with other reasons and were matched for the confoundings of UTI and hypokalemia. We analyze the risk of hypokalemia using logistic regression and calculate the odds ratio (OR) and 95% confidence interval (CI) of OR. RESULTS: We analyzed 43,719 UTI patients and control patients. Hypokalemia was found in 4540 (10.4%) patients with UTI and 1842 (4.2%) control patients. The percentage of patients with hypokalemia was higher in UTI patients (chi-square, p < 0.001). UTI was associated with hypokalemia and the odds ratio (OR) was 2.27 [95% confidence interval (CI): 2.17-2.41]. Cerebrovascular accident, chronic obstructive pulmonary disease, hypertension, congestive heart failure, diarrhea, medications including thiazides, sulfonamides, xanthines, and laxatives were independently associated with hypokalemia. Recurrent UTI was associated with hypokalemia in UTI patients (OR: 1.13, 95% CI: 1.05-1.23, p < 0.001). CONCLUSIONS: Urinary tract infection is associated with hypokalemia among inpatients. The association is independent of patients' comorbidities and medications. Recurrent UTI is associated with increased hypokalemia in UTI patients.


Asunto(s)
Hipopotasemia/complicaciones , Infecciones Urinarias/complicaciones , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia
4.
Neurodegener Dis ; 17(4-5): 166-170, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28467996

RESUMEN

BACKGROUND: We hypothesize that autoantibodies are induced after the blood-brain barrier is damaged by stroke and the risk of bullous pemphigoid (BP) is increased after stroke. We assess the risk of BP after first-ever stroke in a nationwide population-based cohort of first-ever stroke patients. METHODS: We extracted data from the Longitudinal Health Insurance Database 2005 and identified patients with first-ever stroke as well as control patients matched for age, gender, and year of enrollment. The risk of BP in first-ever stroke patients in comparison with that in control patients was analyzed using Cox regression. RESULTS: Of 12,607 patients with first-ever stroke, 38 (0.3%) patients developed BP in a median of 3.5 years. In the control patients, 8 persons (0.06%) had BP in a median of 3.7 years. The crude hazard ratio (HR) of BP in first-ever stroke patients was 4.83 (95% CI 2.25-10.34, p < 0.001) compared to the control group. The adjusted HR was 4.20 (95% CI 1.94-9.08, p < 0.001) after adjustments for age, gender, hypertension, diabetes, dementia, epilepsy, Parkinson disease, furosemide, and neuroleptics for stroke patients. CONCLUSIONS: The risk of BP is increased in first-ever stroke patients in a nationwide population-based cohort and this association is independent of well-known confounders of BP.


Asunto(s)
Penfigoide Ampolloso/epidemiología , Penfigoide Ampolloso/etiología , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/epidemiología , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Planificación en Salud Comunitaria , Femenino , Humanos , Seguro de Salud/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Penfigoide Ampolloso/mortalidad , Modelos de Riesgos Proporcionales , Accidente Cerebrovascular/mortalidad , Análisis de Supervivencia , Taiwán
5.
Seizure ; 29: 86-9, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26076848

RESUMEN

PURPOSE: Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. METHODS: We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. RESULTS: Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p=0.138, χ(2) test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p=0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p=0.482 and p=0.751). CONCLUSION: Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.


Asunto(s)
Anticonvulsivantes/efectos adversos , Fructosa/análogos & derivados , Urolitiasis/inducido químicamente , Urolitiasis/epidemiología , Adulto , Factores de Edad , Anticonvulsivantes/administración & dosificación , Artritis Gotosa/epidemiología , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Fructosa/administración & dosificación , Fructosa/efectos adversos , Humanos , Estimación de Kaplan-Meier , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Factores Sexuales , Taiwán/epidemiología , Factores de Tiempo , Topiramato
6.
Chin Med J (Engl) ; 123(19): 2682-7, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21034653

RESUMEN

BACKGROUND: Valproic acid (VPA) improves early survival and organ function in a highly lethal poly-trauma and hemorrhagic shock model or other severe insults. We assessed whether VPA could improve organ function in a rat model of septic shock and illustrated the possible mechanisms. METHODS: Forty Sprague-Dawley rats were randomly assigned to four groups (n = 10): control group, VPA group, LPS group, and LPS + VPA group. Lipopolysaccharide (LPS) (10 mg/kg) was injected intravenously to replicate the experimental model of septic shock. Rats were treated with VPA (300 mg/kg, i.v.) or saline. Six hours after LPS injection, blood was sampled for gas analysis, measurement of serum alanine aminotransferase, aspartate aminotransferase, urine nitrogen, creatinine and tumor necrosis factor-alpha. Lung, liver and kidney were collected for histopathological assessment. In addition, myeloperoxidase activity and tumor necrosis factor-a in pulmonary tissue were measured. Acetylation of histone H3 in lung was also evaluated by Western blotting. RESULTS: LPS resulted in a significant decrease in PaO2, which was increased by VPA administration followed LPS injection. In addition, LPS also induced an increase in the serum levels of alanine aminotransferase, aspartate aminotransferase, urine nitrogen, creatinine, and tumor necrosis factor-alpha. However, these increases were attenuated in the LPS + VPA group. The lungs, liver and kidneys from the LPS group were significantly damaged compared with the control group. However, the damage was attenuated in the LPS + VPA group. Myeloperoxidase activity and tumor necrosis factor-alpha levels in pulmonary tissue increased significantly in the LPS group compared with the control group. These increases were significantly inhibited in the LPS + VPA group. Acetylation of histone H3 in lung tissue in the LPS group was inhibited compared with the control. However, the level of acetylation of histone H3 in the LPS + VPA group was markedly elevated in contrast to the LPS group. CONCLUSIONS: Treatment with VPA can attenuate multiple organ damage caused by LPS induced septic shock. Our data also suggest that the beneficial effects are in part due to the decrease in inflammatory cytokines and restoration of normal acetylation homeostasis.


Asunto(s)
Insuficiencia Multiorgánica/tratamiento farmacológico , Choque Séptico/tratamiento farmacológico , Ácido Valproico/uso terapéutico , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/metabolismo , Animales , Western Blotting , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Lesión Pulmonar/tratamiento farmacológico , Lesión Pulmonar/metabolismo , Masculino , Insuficiencia Multiorgánica/metabolismo , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Choque Séptico/metabolismo
7.
Acta Neurol Taiwan ; 18(2): 127-9, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19673366

RESUMEN

The pathophysiology of transient global amnesia (TGA) is still speculative. Recently, diffusion-weighted image (DWI) of magnetic resonance imaging (MRI) documented tiny lesions in the hippocampus of patients with TGA in the acute stage. Most studies reported unilateral lesions on MRI. We present one patient of TGA with high signal-intensity lesions in bilateral hippocampus on DWI at the acute stage. The serial findings of brain MRI support the ischemic nature of TGA. Related mechanism about TGA is discussed.


Asunto(s)
Amnesia Global Transitoria/patología , Imagen de Difusión por Resonancia Magnética/métodos , Hipocampo/patología , Amnesia Global Transitoria/etiología , Isquemia Encefálica/complicaciones , Humanos , Masculino , Persona de Mediana Edad
8.
Acta Neurol Taiwan ; 15(2): 114-9, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16871899

RESUMEN

Coexistence of thyrotoxicosis and moyamoya disease is extremely rare. A 23-year-old woman who had a history of migraine, suffered from frequent right carotid transient ischemic attacks, followed by an ischemic stroke after taking ergotamine for migraine. Magnetic resonance angiography revealed a tubular stenosis of the right internal carotid artery (ICA) and bilateral strictures of the supraclinoid segments of the ICAs. A concomitant thyrotoxicosis was found. A second stroke occurred three weeks later, when the dosage of antithyroid medication was increased and phenylpropanolamine-containing cold remedies were taken. Moyamoya disease was confirmed by cerebral angiography which showed irregular tubular stenosis of the right cervical ICA just above the bifurcation and nearly complete occlusion of bilateral supraclinoid ICAs with collateral flows from posterior circulation. The complexity of the cerebral hemodynamics of this patient is discussed.


Asunto(s)
Enfermedad de Graves/complicaciones , Enfermedad de Moyamoya/complicaciones , Tirotoxicosis/complicaciones , Adulto , Circulación Cerebrovascular , Femenino , Humanos , Trastornos Migrañosos/etiología , Accidente Cerebrovascular/etiología
9.
Sheng Wu Gong Cheng Xue Bao ; 19(4): 428-32, 2003 Jul.
Artículo en Chino | MEDLINE | ID: mdl-15969059

RESUMEN

The effects of the Smad3- knockout on the hematopoiesis of mouse were investigated in this work. Five pairs of wild type and Smad3- null mice were studied. White blood cell(WBC), red blood cell(RBC) and platelet (PLT) counting of peripheral blood cells were performed with blood obtained from tails. And white blood cells were classified by their morphology. Bone marrow nucleated cells (BMNCs) were counted and classified. The CFU-GM, BFU-E, CFU-GEMM yields were measured in each pair of mice. CFU-S yield of each mouse was measured by injecting bone marrow cells into lethally irradiated 8-10 weeks old wild type female mice. And the pathomorphism of their bone marrows, spleens and livers were observed. As a result, WBC and PLT of Smad3- null mice were significantly higher than those in wild type mice. Smad3- null mice had much more proportion of granulocytes in classification. There wasn't any difference in RBC counting and BFU-E measurement. The yield of CFU-GM increased, while the yields of CFU-GEMM and CFU-S markedly reduced. Bone marrows are actively proliferative, with granulocytosis. The granulocyte/erythrocyte ratio increased. There were no obviously alterative in spleen and liver. Thus Smad3- knockout results in a decreased number of stem and progenitor cells. Moreover hematopoietic differentiation is abnormal with a tendency to forming more granulocytes and platelets. The effect of Smad3 on hematopoiesis is correlative to that of TGF-beta.


Asunto(s)
Hematopoyesis/genética , Proteína smad3/genética , Animales , Células de la Médula Ósea/citología , Células de la Médula Ósea/metabolismo , Diferenciación Celular , Eritrocitos/citología , Eritrocitos/metabolismo , Células Precursoras Eritroides/citología , Células Precursoras Eritroides/metabolismo , Femenino , Células Progenitoras de Granulocitos y Macrófagos/citología , Células Progenitoras de Granulocitos y Macrófagos/metabolismo , Granulocitos/citología , Granulocitos/metabolismo , Ratones , Ratones Noqueados , Células Progenitoras Mieloides/citología , Células Progenitoras Mieloides/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...